Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Drug and drug composition for treating epstein-barr virus-positive diffuse large B-cell lymphoma (EBV+DLBCL) and diffuse large B-cell lymphoma (DLBCL)

A composition and drug technology, applied in the field of biomedicine, can solve problems such as lack of use in the treatment of immune function, etc.

Active Publication Date: 2017-09-15
CHINA PHARM UNIV
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are still relatively few reports on the treatment of EBV+DLBCL with this regimen.
Immunotherapy with EBV-specific cytotoxic T lymphocytes, which successfully prevents lymphoma after organ transplantation and treats EBV-associated lymphoma, has not been used in immunocompetent DLBCL patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug and drug composition for treating epstein-barr virus-positive diffuse large B-cell lymphoma (EBV+DLBCL) and diffuse large B-cell lymphoma (DLBCL)
  • Drug and drug composition for treating epstein-barr virus-positive diffuse large B-cell lymphoma (EBV+DLBCL) and diffuse large B-cell lymphoma (DLBCL)
  • Drug and drug composition for treating epstein-barr virus-positive diffuse large B-cell lymphoma (EBV+DLBCL) and diffuse large B-cell lymphoma (DLBCL)

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0066] Experimental conditions: 5000 Farage cells were placed in each well of a 96-well plate, and CAPE was added to treat the Farage cells. Farage cell proliferation is inhibited, and the inhibition rate is as follows figure 1 As shown, the IC50 was 2.42 μM.

Embodiment 2

[0068] Experimental conditions: 5,000 MC116 cells were placed in a 96-well plate, and CAPE was added to treat MC116 cells. MC116 cells were EBV-DLBCL cells. After 48 hours, Alamar Blue was added to measure the inhibitory rate of the drug on the cells. It was found that CAPE had The proliferation of MC116 cells can be inhibited, and the inhibition rate is as follows figure 2 As shown, the IC50 was 1.26 μM.

Embodiment 3

[0070] Experimental conditions: 5000 SUDHL-2 cells were placed in a 96-well plate, and CAPE was added to treat SUDHL-2 cells. SUDHL-2 cells were EBV-DLBCL cells. Alamar Blue was added after 48 hours to measure the effect of drugs on cells. Inhibition rate, it was found that CAPE had an inhibitory effect on the proliferation of SUDHL-2 cells, and the inhibition rate was as follows image 3 As shown, the IC50 was 0.304 μM.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a drug for treating epstein-barr virus-positive diffuse large B-cell lymphoma (EBV+DLBCL), a drug composition for treating the DLBCL and a drug for treating the DLBCL, wherein the drugs for treating the EBV+DLBCL and the DLBCL are caffeic acid phenethyl ester (CAPE) and derivatives thereof and the drug composition contains the CAPE and the derivatives thereof and cyclophosphamide, hydroxydaunorubicin, oncovino and prednisone or prednisolone) (CHOP). Proved by pharmacological tests, the CAPE has an obvious inhibiting effect on cell proliferation when being used for treating EBV+DLBCL cells and EBV-DLBCL cells; when the CAPE and the CHOP are combined to treat the EBV+DLBCL cells, the sensitivity of the EBV+DLBCL cells to the CHOP is increased by the CAPE; when the CAPE and the CHOP are combined to treat the EBV-DLBCL cells, the sensitivity of the EBV-DLBCL cells to the CHOP is increased by the CAPE; and the CAPE has an obvious inhibiting effect on tumor body growth when being used for treating Farage cell transplantation tumors.

Description

technical field [0001] The invention relates to a medicine and composition for treating EBV+DLBCL and DLBCL, belonging to the technical field of biomedicine. Background technique [0002] Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in adults. It accounts for about 30% of all non-Hodgkin's lymphomas, with an average annual incidence of 7-8 cases per 100,000 people. The standard chemotherapy regimen (CHOP) including cyclophosphamide, doxorubicin, vincristine, and prednisone has helped more than 40% of DLBCL patients achieve long-term survival. In addition, the addition of rituximab to the CHOP regimen (R-CHOP) has increased the 5-year survival rate of DLBCL patients to nearly 60%. Although the prognosis of patients has been greatly improved with the progress of treatment options, about one-third of patients still eventually die of drug resistance or disease relapse. [0003] Epstein-Barr virus (EBV)-positive diffuse large B-ce...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/216A61K31/675A61K31/704A61K31/475A61K31/573A61K31/519A61K31/7048A61K31/7068A61K31/166A61K31/136A61P35/00
CPCA61K31/136A61K31/166A61K31/216A61K31/475A61K31/519A61K31/573A61K31/675A61K31/704A61K31/7048A61K31/7068A61K2300/00
Inventor 吴亮陈星光胡蝶汪小燕王雨轩王呈呈廖有为李成婧牟畅丁赣成俞婧婷张陆勇
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com